Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ELAN | Elanco Animal Health Inc | 2025-10-30 15:38:45 | 22.57 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELAN | 0001739104 | Elanco Animal Health Inc | US28414H1032 | 549300SHPNDCE059M934 | 825497352 | NYSE | 2834 | Pharmaceutical Preparations | 1231 | — | 2500 INNOVATION WAY | GREENFIELD | IN | 46140 | UNITED STATES | US | 877-352-6261 | 2500 INNOVATION WAY, GREENFIELD, IN, 46140 | 2500 INNOVATION WAY, GREENFIELD, IN, 46140 | — | Pharmaceutical (animal) | 1954 | Jeff Simmons | 10,200 | http://elanco.com | 7,100,000,000 | 496,646,312 | 496,813,702 | Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world. | 2025-10-30 12:58:29 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 7,100,000,000 | 2,200,000,000 | 44.898 | 494,613,940 | 1,643,929 | 0.3335 |
| 2023 | 4,900,000,000 | -4,400,000,000 | -47.3118 | 492,970,011 | 1,426,510 | 0.2902 |
| 2022 | 9,300,000,000 | -7,100,000,000 | -43.2927 | 491,543,501 | 18,356,749 | 3.8794 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Ellen De Brabander | Executive Vice President | 2024 | 753,048 | 0 | 2,031,537 | 581,730 | 37,115 | 3,913,932 |
| Ramiro Cabral | President, Executive Vice President | 2024 | 620,000 | 0 | 1,361,268 | 478,950 | 28,501 | 2,942,471 |
| Jeffrey Simmons | CEO, President | 2024 | 1,200,000 | 0 | 9,000,027 | 1,606,800 | 26,871 | 14,833,704 |
| Todd Young | Chief Financial Officer, Executive Vice President | 2024 | 694,000 | 0 | 2,111,279 | 571,856 | 28,471 | 4,109,361 |
| Timothy Bettington | Executive Vice President | 2024 | 642,000 | 0 | 1,050,029 | 462,882 | 28,471 | 2,533,389 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 9,000 |
| 2023 | 9,300 |
| 2022 | 9,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 4,439,000,000 | 4,417,000,000 | 4,411,000,000 |
| Cost Of Revenue | 2,003,000,000 | 1,931,000,000 | 1,913,000,000 |
| Gross Profit | 2,436,000,000 | — | — |
| Research And Development Expenses | 344,000,000 | 327,000,000 | 321,000,000 |
| General And Administrative Expenses | 1,314,000,000 | 1,285,000,000 | 1,265,000,000 |
| Operating Expenses | 3,951,000,000 | 5,612,000,000 | 4,483,000,000 |
| Operating Income | — | — | — |
| Net Income | 338,000,000 | -1,231,000,000 | -78,000,000 |
| Earnings Per Share Basic | 0.68 | -2.5 | -0.16 |
| Earnings Per Share Diluted | 0.68 | -2.5 | -0.16 |
| Weighted Average Shares Outstanding Basic | 494,000,000 | 492,300,000 | 488,300,000 |
| Weighted Average Shares Outstanding Diluted | 497,300,000 | 492,300,000 | 488,300,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 468,000,000 | 352,000,000 | 345,000,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 805,000,000 | 842,000,000 | 797,000,000 |
| Inventories | 1,574,000,000 | 1,735,000,000 | 1,538,000,000 |
| Non Trade Receivables | 121,000,000 | 149,000,000 | 180,000,000 |
| Other Assets Current | — | — | — |
| Total Assets Current | 3,215,000,000 | 3,407,000,000 | 3,279,000,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 993,000,000 | 1,026,000,000 | 999,000,000 |
| Other Assets Non Current | 311,000,000 | 341,000,000 | 378,000,000 |
| Total Assets Non Current | 9,399,000,000 | 10,955,000,000 | 12,212,000,000 |
| Total Assets | 12,614,000,000 | 14,362,000,000 | 15,491,000,000 |
| Accounts Payable | 296,000,000 | 270,000,000 | 390,000,000 |
| Deferred Revenue | 332,000,000 | 367,000,000 | 324,000,000 |
| Short Term Debt | 44,000,000 | 38,000,000 | 388,000,000 |
| Other Liabilities Current | 466,000,000 | 409,000,000 | 454,000,000 |
| Total Liabilities Current | 1,315,000,000 | 1,241,000,000 | 1,702,000,000 |
| Long Term Debt | 4,321,000,000 | 5,774,000,000 | 5,836,000,000 |
| Other Liabilities Non Current | 302,000,000 | 411,000,000 | 229,000,000 |
| Total Liabilities Non Current | 5,203,000,000 | 6,898,000,000 | 6,500,000,000 |
| Total Liabilities | 6,518,000,000 | 8,139,000,000 | 8,202,000,000 |
| Common Stock | 0 | 0 | 0 |
| Retained Earnings | -1,950,000,000 | -2,288,000,000 | -1,057,000,000 |
| Accumulated Other Comprehensive Income | -771,000,000 | -266,000,000 | -392,000,000 |
| Total Shareholders Equity | 6,096,000,000 | 6,223,000,000 | 7,289,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 662,000,000 | 694,000,000 | 682,000,000 |
| Share Based Compensation Expense | 55,000,000 | 46,000,000 | 59,000,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | -12,000,000 | 40,000,000 | -14,000,000 |
| Change In Inventories | -44,000,000 | 160,000,000 | 269,000,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -11,000,000 | 6,000,000 | 109,000,000 |
| Change In Accounts Payable | — | — | — |
| Change In Other Liabilities | — | 0 | 0 |
| Cash From Operating Activities | 541,000,000 | 271,000,000 | 452,000,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 147,000,000 | 140,000,000 | 137,000,000 |
| Acquisition Of Business | 41,000,000 | 19,000,000 | 0 |
| Other Investing Activities | 0 | -4,000,000 | 8,000,000 |
| Cash From Investing Activities | 1,158,000,000 | -169,000,000 | -179,000,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | 0 | 0 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 350,000,000 | — | 425,000,000 |
| Repayment Of Long Term Debt | 250,000,000 | 150,000,000 | 813,000,000 |
| Other Financing Activities | -17,000,000 | -6,000,000 | -16,000,000 |
| Cash From Financing Activities | -1,492,000,000 | -83,000,000 | -549,000,000 |
| Change In Cash | 116,000,000 | 7,000,000 | -293,000,000 |
| Cash At End Of Period | 468,000,000 | 352,000,000 | 345,000,000 |
| Income Taxes Paid | 140,000,000 | 95,000,000 | 93,000,000 |
| Interest Paid | 296,000,000 | 379,000,000 | 266,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | 0.68 | -2.5 | -0.16 |
| Price To Earnings Ratio | 17.8088 | -5.96 | -76.375 |
| Earnings Growth Rate | -127.2 | 1,462.5 | -83.5052 |
| Price Earnings To Growth Ratio | -0.14 | -0.0041 | 0.9146 |
| Book Value Per Share | 12.3401 | 12.6407 | 14.9273 |
| Price To Book Ratio | 0.9814 | 1.1787 | 0.8186 |
| Ebitda | 1,140,000,000 | -165,000,000 | 938,000,000 |
| Enterprise Value | 9,879,340,000 | 12,795,270,000 | 11,846,026,000 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.716 | 0.934 | 0.8539 |
| Capital Expenditures | 629,000,000 | 721,000,000 | 620,000,000 |
| Free Cash Flow | -88,000,000 | -450,000,000 | -168,000,000 |
| Return On Equity | 0.0554 | -0.1978 | -0.0107 |
| One Year Beta | 1.0337 | 1.9487 | 1.0231 |
| Three Year Beta | 1.1999 | 1.1418 | 1.0134 |
| Five Year Beta | 1.0865 | 1.0731 | 0.9689 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Modi Rajeev A. | — | 2025-10-17 | 66 | A | 7,099 |
| Simmons Jeffrey N | Director, PRESIDENT, CEO AND DIRECTOR | 2025-10-17 | 129 | A | 18,099 |
| Simmons Jeffrey N | Director, PRESIDENT, CEO AND DIRECTOR | 2025-10-03 | 134 | A | 17,970 |
| Modi Rajeev A. | — | 2025-10-03 | 68 | A | 7,033 |
| VanHimbergen Robert M | EVP and CFO | 2025-10-01 | 109,857 | A | 109,857 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Daniel S Sullivan | Senator | 2023-07-26 | Sale (Full) | 2022-11-30 | Joint | $1,001 - $15,000 |
| Daniel S Sullivan | Senator | 2022-12-21 | Sale (Full) | 2022-11-30 | Joint | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Valerie Hoyle | 2025-10-10 | OR04 | Sale | 2025-09-23 | Spouse | $1,001 - $15,000 |
| Daniel Goldman | 2023-04-17 | NY10 | Sale (Partial) | 2023-03-06 | — | $1,001 - $15,000 |
| Susie Lee | 2022-12-29 | NV03 | Sale | 2022-11-30 | Joint | $1,001 - $15,000 |
| Alan S. Lowenthal | 2019-09-01 | CA47 | Sale | 2019-08-20 | Spouse | $15,001 - $50,000 |
| Alan S. Lowenthal | 2019-09-01 | CA47 | Sale | 2019-08-20 | Spouse | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| JENNISON ASSOCIATES LLC | 2025-09-30 | 80,043,348 | 3,974,347 | 20.14 |
| HUNTER ASSOCIATES INVESTMENT MANAGEMENT LLC | 2025-09-30 | 233,000 | 11,600 | 20.0862 |
| TEACHER RETIREMENT SYSTEM OF TEXAS | 2025-09-30 | 1,357,214 | 67,389 | 20.14 |
| Probity Advisors, Inc. | 2025-09-30 | 432,768 | 21,488 | 20.14 |
| Parkside Financial Bank & Trust | 2025-09-30 | 30,413 | 1,510 | 20.1411 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Global X Funds | 2025-08-31 | Global X Adaptive U.S. Factor ETF | AUSF | 227,687 | 4,178,056.45 | 0.604 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-08-31 | SIIT Multi-Asset Real Return Fund - Class A | SEIAX | 4,345 | 79,730.75 | 0.0105 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-08-31 | SIIT LARGE CAP INDEX FUND - CLASS A | LCIAX | 16,637 | 305,288.95 | 0.0168 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-08-31 | SIIT U.S. Equity Factor Allocation Fund - Class A | SEHAX | 49,457 | 907,535.95 | 0.0318 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-08-31 | SIIT Extended Market Index Fund - Class A | SMXAX | 75,000 | 1,376,250 | 0.1136 |